In connection to the interim results of the clinical study SPAGOPIX-01, the company invites to a live webcast today at 13:00. CEO Mats Hansen will present and comment the results, and provide opportunity for questions.

The webcast can be reached by: https://www.finwire.tv/webcast/spago-nanomedical/q3/.

The webcast will be available afterwards at the home page of Spago Nanomedical.

For further information, please contact: Mats Hansen, CEO Spago Nanomedical AB (publ), +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Spotlight Stock Market in Stockholm (ticker: SPAG). For further information, see www.spagonanomedical.se.